| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 11.2% | -2.7% | -2.7% |
Summers Value Fund returned -2.7% net in Q1 2026, underperforming small-cap benchmarks but maintaining strong long-term performance with 11.2% annualized returns since inception versus 6.8% for the Russell 2000. The fund's concentrated approach focuses on small-cap healthcare and medical device companies trading at attractive valuations. Key contributors included Liquidia, Avanos Medical, and Consensus Cloud Solutions, while Electromed and Embecta detracted. The quarter's highlight was Avanos Medical's acquisition by American Industrial Partners for $25 per share, representing a 72% premium and 106% gain on the fund's position. The manager initiated a new position in Theravance, a COPD-focused company with long-duration cash flows from Yupelri royalties. With nine long positions and 5% cash, the fund maintains a concentrated portfolio targeting companies with strong fundamentals trading below intrinsic value. The manager expects healthcare M&A to remain a significant tailwind, with seven portfolio companies acquired since inception. The strategy has ample capacity and welcomes patient, long-term oriented investors.
Concentrated small-cap value investing in healthcare and medical device companies trading at attractive valuations, with M&A activity serving as a key catalyst for value realization.
The manager believes the M&A theme in healthcare will be a tailwind that could benefit the portfolio for many years. The current market environment is providing attractive investment opportunities, and the strategy has ample capacity for new investors.
| Date | Letter | Tickers | Keywords | Pitches | Quick Takes |
|---|---|---|---|---|---|
| Apr 1 2026 | 2026 Q1 | AVNS, TBPH | healthcare, M&A, Medical Devices, Pharmaceuticals, small caps, value |
AVNS TBPH AVNS TBPH |
Concentrated small-cap healthcare value fund delivered strong long-term returns despite Q1 underperformance. Avanos Medical takeout at 72% premium exemplifies M&A-driven value realization strategy. New Theravance position offers 60% upside potential from COPD royalties. Nine-position portfolio targets undervalued medical device and pharmaceutical companies with M&A catalysts expected to drive future returns. |
| Jan 12 2026 | 2025 Q4 | CCSI, DPLO, ELMD, ENDP, NVO | concentrated, healthcare, long-term, small caps, special situations, value | - | Summers Value Fund targets small-cap healthcare special situations with 12.0% annualized returns since 2018 inception versus 6.9% for Russell 2000. Concentrated portfolio focuses on undervalued companies undergoing positive change with limited institutional coverage. Strong downside protection through fundamental analysis and margin of safety approach while capturing asymmetric upside in inefficient small-cap healthcare markets. |
| Jan 12 2026 | 2025 Q4 | CCSI, DPLO, ELMD, ENDP, NVO | concentrated, healthcare, long-term, small caps, special situations, value | CCSI | Summers Value Fund targets small-cap healthcare special situations with 12.0% annualized returns since 2018 inception versus 6.9% for Russell 2000. Concentrated portfolio focuses on undervalued companies undergoing positive change with limited institutional coverage. Strong downside protection through fundamental analysis and margin of safety approach while capturing asymmetric upside in inefficient small-cap healthcare markets. |
| Nov 8 2025 | 2025 Q3 | ADMA, CCSI, DERM, ELMD, INSP, LGND, LQDA, QURE, SPOK, SPRY, UFPT, ZIMV | Biotechnology, healthcare, innovation, M&A, Pharmaceuticals, Regulatory, small cap, value | - | Summers Value Fund capitalized on healthcare sector distress to deliver 20.4% Q3 returns. Regulatory uncertainty and record fund outflows created opportunities in undervalued small-cap healthcare companies. The fund increased biopharma exposure to 40% of portfolio, betting on innovation cycles and M&A premiums while positioning for long-term outperformance in a fundamentally defensive, growing sector. |
| Sep 2 2025 | 2025 Q2 | ADMA, CCSI, DERM, ELMD, INSP, LGND, OTCM, SPOK, VSTS, ZIMV | Biotech, healthcare, Pharmaceuticals, small caps, underperformance, value |
DERM DERM |
Summers Value Fund underperformed in Q2 with -1.8% returns versus Russell 2000's 8.5% gain, bringing YTD to -12.8%. Healthcare holdings faced sector headwinds from administration policy uncertainty. Portfolio trades at widest discount to intrinsic value since mid-2022. Manager remains optimistic on fundamentally strong businesses despite near-term performance challenges. |
| Apr 30 2025 | 2025 Q1 | ADMA, CCSI, ELMD, INDV, LQDA, SPOK, VSTS, ZIMV | Biotechnology, Defensive, healthcare, small caps, value | CCSI | Summers Value Fund's healthcare-focused strategy faced headwinds in Q1 2025 from regulatory concerns, returning -11.2% net. The manager views the selloff as overdone, adding to high-conviction positions like Consensus Cloud Solutions trading at attractive 4.3x earnings. Elevated cash provides flexibility to capitalize on market weakness in defensive healthcare companies with strong fundamentals. |
| Dec 31 2024 | 2024 Q4 | AAPL, AMZN, CCSI, ELMD, GOOGL, INDV, ISRG, LFCR, META, MODV, MSFT, NVDA, OTCM, PINC, SPOK, UFPT, UTMD, VSTS, ZBH, ZIMV | healthcare, Long/Short, Medical Devices, small caps, value |
ELMD UFPT INDV ZIMV |
Summers Value Fund returned 27.4% in 2024, outperforming small-cap benchmarks through concentrated small-cap value investing. Strong performance from medical device holdings like Electromed and UFP Technologies, plus profitable shorts. Manager believes small-caps are positioned to outperform large-caps due to attractive valuations and expected M&A uptick under new administration. |
| Feb 27 2024 | 2023 Q4 | ELMD, FRPT, INSP, ISDR, LFCR, MODV, OTCM, PINC, SPOK, UFPT, UTMD, VRTV, ZIMV | Biotechnology, dividends, healthcare, Long/Short, Medical Devices, small caps, value | ASIC|CWAN|INSP|KRMN|KTOS|MAC|MEG|RH|WYNN | Small-cap value fund returned 16.1% in 2023, outperforming value benchmarks through concentrated positions in quality businesses. Strong performance from medical device holdings including Spok and UFP Technologies. Added Inspire Medical on GLP-1 fears the manager believes are misplaced. Portfolio focused on undervalued small-caps with growth potential and strong balance sheets. |
| Jan 31 2023 | 2022 Q4 | LFCR, UFPT, UTMD | - | - | |
| Dec 31 2021 | 2021 Q4 | MODV, NOTV, PLXP, UFPT, UTMD | - | - | |
| Dec 31 2020 | 2020 Q4 | BASI, ELMD, MODV | - | - |
| QUARTER | THEMES | TAGS |
|---|---|---|
| 2026 Q1 |
Biopharma M&AThe manager expects M&A activity in healthcare to be a significant tailwind for the portfolio for many years. Seven portfolio companies have been acquired since inception, with Avanos Medical recently acquired for a 72% premium. The manager views M&A as an important contributor to future returns. |
Healthcare Acquisitions Takeouts Premium Strategic |
Small CapsThe fund focuses exclusively on small-cap investments, with nine long positions at quarter-end including companies like Liquidia, Electromed, and Consensus Cloud Solutions. The manager sees attractive opportunities in the current small-cap environment and believes the strategy has ample capacity. |
Russell 2000 Value Concentrated Opportunities Capacity | |
ValueThe fund employs a value-focused strategy, seeking companies trading at attractive valuations. The manager describes finding Avanos at less than 1x EV/Sales and 7x normalized earnings, representing valuations rarely seen in the medical device industry. The approach focuses on patient capital and long-term value realization. |
Valuation Undervalued Patient Long-term Intrinsic | |
| 2025 Q4 |
Biopharma M&AM&A activity accelerated in the second half with notable acquisitions including Merck's $10 billion purchase of Verona Pharmaceuticals and Sanofi's $9.5 billion acquisition of Blueprint Medicines. Manager believes acquisitions will play a key role in filling the void created by patent expirations as big pharma faces the largest patent cliff in industry history, potentially losing $400 billion in revenue by 2030. |
M&A Acquisitions Patent Cliff Big Pharma Biotech |
BiotechnologyFund's allocation to pharmaceutical and biotechnology stocks increased significantly to over 40% by year end. Manager believes small-cap biotech and pharma stocks are on the front end of a multi-year innovation cycle with recent drug launches having blockbuster revenue potential of $1 billion plus. |
Small-cap Innovation Drug Launches Blockbuster Revenue | |
PharmaceuticalsHealthcare sector faced significant pressure in first half due to regulatory uncertainty and government proposals to curtail drug prices, but recovered strongly in second half. Manager focuses on identifying businesses more insulated from macro and regulatory factors positioned to compound value through various environments. |
Drug Pricing Regulatory Healthcare Value Compounding | |
| 2025 Q4 |
HealthcareFund focuses exclusively on small-cap healthcare companies representing special situations. Uses fundamental research to identify unrecognized value in companies undergoing positive change including spin-offs, asset sales, business model pivots, and new product launches. Portfolio concentrated in pharmaceutical, medical device, biotechnology, and healthcare IT companies. |
Healthcare Medical Devices Biotechnology Pharmaceuticals Healthcare IT |
ValueFund employs rigorous valuation approach focusing on downside protection relative to estimate of intrinsic value using cash flow yield or asset value. Seeks margin of safety based on valuation discount, growth opportunities and strong management. Invests where most institutional managers can't or won't participate. |
Value Investing Intrinsic Value Margin of Safety Cash Flow Valuation | |
Small CapsConcentrated portfolio of small-cap companies with limited sell-side coverage and institutional ownership. 44% of Russell 2000 stocks have zero Wall Street coverage, creating mispriced opportunities. Fund operates in less efficient markets where under-followed stocks create opportunities for investors willing to look beyond Wall Street's focus. |
Small Cap Russell 2000 Market Inefficiency Coverage Opportunity | |
AIFund uses new AI tools to identify and research underfollowed investment opportunities in their screening and research process. |
AI Tools Research Screening | |
| 2025 Q3 |
BiotechnologyThe fund has increased portfolio exposure to biopharma stocks following years of underperformance, believing they are poised for outperformance. The manager is optimistic about the innovation cycle and recognizes that large-cap companies will pay sizeable premiums to acquire attractive pipelines with large sales opportunities. |
Gene Therapy Drug Development Clinical Trials Pharmaceutical Innovation M&A |
PharmaceuticalsThe fund focuses on pharmaceutical royalty companies and drug development opportunities. Key holdings include companies with promising drug launches like Ohtuvaryre for COPD and Filspari for nephropathy, both expected to reach blockbuster status over time. |
Royalty Aggregator Drug Launches COPD Nephropathy Blockbuster Drugs | |
| 2025 Q2 |
PharmaceuticalsThe fund holds multiple pharmaceutical positions including Ligand Pharmaceuticals, ADMA Biologics, and Journey Medical. Healthcare sector sentiment remains weak amid uncertainty from new administration proposals to curb drug pricing and cut Medicare/Medicaid reimbursement. The fund initiated two short positions in pharmaceutical companies where sales expectations are believed to be too high. |
Drug Pricing FDA Dermatology Rosacea Biotech |
Small CapsThe fund focuses on small-cap investments, benchmarking against the Russell 2000 Index. Portfolio companies have market caps in the hundreds of millions, with Journey Medical at $160 million being representative. The fund has delivered 9.7% annualized returns since inception compared to 5.3% for the Russell 2000. |
Russell 2000 Market Cap Undervalued Value Investing Long Term | |
ValueThe portfolio is currently trading at the widest discount to intrinsic value since mid-2022. Despite difficult performance, the manager believes businesses remain fundamentally strong with low valuations. The fund targets undervalued companies with solid fundamentals and long-term capital growth potential. |
Intrinsic Value Discount Fundamentals Undervalued Capital Growth | |
| 2025 Q1 |
HealthcareThe Fund focuses on relatively defensive healthcare companies that have historically served as a safe harbor during market uncertainty. Recent selloff in healthcare stocks following FDA leadership changes and concerns over drug approvals is viewed as overdone. Portfolio consists of companies with predictable businesses and strong cash flow generation. |
Healthcare IT Biotechnology Medical Devices Pharmaceuticals Healthcare Software |
ValueFund employs concentrated, long-term value approach targeting companies trading at attractive valuations. Current holdings offer compelling metrics including 4.3x earnings and 11% free cash flow yields. Manager views current market weakness as presenting attractive entry points for long-term investors. |
Value Small Caps Quality Earnings Buybacks | |
| 2024 Q4 |
Small CapsManager believes small-cap stocks are well-positioned to outperform relative to large-cap stocks going forward, driven by lower valuations, poor sentiment, and an expected uptick in M&A under the new administration. Small-cap stocks continued a multi-year trend of underperformance in 2024. |
Value M&A Outperformance Undervaluation Sentiment |
Medical DevicesFund holds multiple medical device companies including Electromed (respiratory devices), UFP Technologies (medical device components), and Zimvie (dental implants). These companies benefit from growing markets, superior product profiles, and strategic relationships with larger medical companies. |
Healthcare Growth Innovation Partnerships Specialization | |
ValueStrategy focuses on business quality and positive change factors combined with long-term investment orientation. Manager seeks companies trading at attractive valuations with potential for improvement in fundamentals or strategic alternatives. |
Quality Change Long-term Fundamentals Undervaluation | |
| 2023 Q4 |
Medical DevicesThe fund has significant exposure to medical device companies including UFP Technologies (linked to da Vinci surgical robot growth), Inspire Medical (sleep apnea devices), and Zimvie (spine and dental). The manager sees strong growth potential in surgical robotics and sleep apnea treatment markets. |
Surgical Robotics Sleep Apnea Medical Technology Healthcare Innovation Device Manufacturing |
GLP1The manager discusses GLP-1 drugs extensively in relation to Inspire Medical, believing they will represent the largest drug class in pharmaceutical history. However, he argues that GLP-1 adoption will likely increase rather than decrease the patient pool for sleep apnea devices. |
Weight Loss Obesity Pharmaceutical Drug Development Patient Pool | |
BiotechnologyThe fund holds positions in biotech-related companies including Lifecore Biomedical (CDMO specializing in fill-finish of viscous drugs) and Utah Medical (biomedical processing business). The manager notes challenges in the biotechnology tools and services industry affecting Utah Medical's performance. |
CDMO Contract Manufacturing Bioprocessing Drug Development Life Sciences |
| Date | Pitch Type | Author | Ticker | Company | Industry | Sub Industry | Bull / Bear | Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 25, 2026 | Fund Letters | Summers Value Fund | AVNS | Avanos Medical | Medical Devices | Health Care Equipment | Bull | NASDAQ | Enteral Feeding, healthcare, M&A, Medical devices, private equity, spin-off, turnaround, Value | Login |
| Apr 25, 2026 | Fund Letters | Summers Value Fund | TBPH | Theravance | Biotechnology | Biotechnology | Bull | NASDAQ | biotechnology, cash flow, China, Copd, patent protection, restructuring, royalties, strategic review | Login |
| Apr 1, 2026 | Fund Letters | Summers Value Fund | TBPH | Theravance | Biotechnology | Biotechnology | Bull | NASDAQ | biotechnology, cash flow, China, Copd, patent protection, restructuring, royalties, strategic review | Login |
| Apr 1, 2026 | Fund Letters | Summers Value Fund | AVNS | Avanos Medical | Medical Devices | Health Care Equipment | Bull | NASDAQ | Enteral Feeding, healthcare, M&A, Medical devices, private equity, spin-off, turnaround, Value | Login |
| Jan 12, 2026 | Fund Letters | Andrew Summers | CCSI | Consensus Cloud Solutions Inc. | Information Technology | Application Software | Bull | NASDAQ | buybacks, deleveraging, Healthcareit, rerating, spin-off | Login |
| Sep 2, 2025 | Fund Letters | Andrew Summers | DERM | Journey Medical Corporation | Health Care | Specialty Pharmaceuticals | Bull | NASDAQ | dermatology, Druglaunch, FDA, growth, pharmaceuticals | Login |
| Jul 1, 2025 | Fund Letters | Summers Value Fund | DERM | Journey Medical Corporation | Health Care | Pharmaceuticals | Bull | NASDAQ | Commercial Launch, dermatology, FDA approval, patent protection, pharmaceuticals, Revenue Growth, rosacea treatment, Specialty pharma, turnaround | Login |
| Apr 1, 2025 | Fund Letters | Summers Value Fund | CCSI | Consensus Cloud Solutions | Information Technology | Application Software | Bull | NASDAQ | AI, cloud services, debt reduction, Digital transformation, Fax Technology, Free Cash Flow, Healthcare IT, SaaS, Share Buybacks, Value | Login |
| Jan 1, 2025 | Fund Letters | Summers Value Fund | UFPT | UFP Technologies | Materials | Specialty Chemicals | Bull | NASDAQ | Acquisitions, deleveraging, Intuitive Surgical Partnership, manufacturing, Medical Device Components, specialty materials, Value | Login |
| Jan 1, 2025 | Fund Letters | Summers Value Fund | INDV | Indivior | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals | Bull | NASDAQ | contrarian, FDA approval, Long-Acting Buprenorphine, Opioid Addiction Treatment, pharmaceuticals, Sublocade, underpenetrated market, Value | Login |
| Jan 1, 2025 | Fund Letters | Summers Value Fund | ZIMV | Zimvie | Health Care Equipment & Services | Health Care Equipment | Bull | NASDAQ | balance sheet improvement, Dental-Implants, M&A Target, Medical devices, spin-off, turnaround, Value | Login |
| Jan 1, 2025 | Fund Letters | Summers Value Fund | ELMD | Electromed | Health Care Equipment & Services | Health Care Equipment | Bull | NASDAQ | Bronchiectasis, growth, Healthcare Equipment, market share gains, Medical devices, Respiratory Therapy, SmartVest | Login |
| Feb 1, 2024 | Fund Letters | Summers Value Fund | ASIC|CWAN|INSP|KRMN|KTOS|MAC|MEG|RH|WYNN | Inspire Medical | Health Care Equipment & Supplies | Health Care Equipment | Bull | NASDAQ | growth, Healthcare Technology, market leader, Medical Device, Neurostimulation, sleep apnea, turnaround | Login |
| TICKER | COMMENTARY |
|---|---|
| AVNS | Avanos was formerly the healthcare division of Kimberly-Clark before being spun off as a separate company in 2014. The company has been a tale of two businesses: a high-quality enteral feeding segment with a dominant global market position featuring mid-single-digit revenue growth and a double-digit operating margin, and a structurally challenged hospital pain segment with stagnant revenue and breakeven profitability. On April 14, Avanos agreed to be acquired by American Industrial Partners for $25 per share in an all-cash transaction, representing a 72% premium. Our cost basis is $12.15, which represents a gain of 106% at the takeout price. |
| TBPH | Theravance markets Yupelri for COPD in partnership with Viatris. We initiated our position on March 3, after the company announced that its lead development program, ampreloxetine, had failed its pivotal phase 3 clinical trial. Beginning in the third quarter of 2026, Yupelri royalties, combined with interest income, are expected to generate $60-70 million of annual cash flow. With patent protection extending through April of 2039, Yupelri represents a long-duration and growing cash flow stream. We estimate intrinsic value at $23 per share, or more than 60% upside from our cost basis of $13.80. |
| Ticker | Put/Call | Amount Bought | Shares Bought | % Change | Weight % |
|---|---|---|---|---|---|
| No Recent Buys Data | |||||
| Ticker | Put/Call | Amount Sold | Shares Sold | % Change | Weight % | Status |
|---|---|---|---|---|---|---|
| No Recent Sells Data | ||||||
| Industry | Prev Quarter % | Current Quarter % | Change |
|---|---|---|---|
| No industry data available | |||
